Search
Seattle based Shape Therapeutics is aiming to reprogram cells by delivering guide RNAs via AAV - it has partnerships with Otsuka and Roche
Ron Hause, SVP, Head of AI, describes Shape's approach, which is meant to be a one time treatment without introducing any inheritable DNA...
Oct 1, 2024
Dyno Therapeutics is using AI to develop next generation AAV vectors for gene therapies
Co-Founder & CSO Adrian Veres and Head of Stewardship Tyson Bertmaring describe the shortcomings of wild type AAV that Dyno is trying to...
Oct 1, 2024
Benchling Co-Founder and CEO Sajith Wickramasekara kicks off Benchtalk 2024 and highlights new feature announcements for this software platform that powers the biotech sector
He describes the three main areas of Benchling's new features: Scaling the wet lab, powering the dry lab, and creating an open platform...
Oct 1, 2024
ARS Pharmaceuticals recently received FDA approval for neffy, epinephrine in a nasal spray format for the treatment of allergic reactions like anaphylaxis
CEO Richard Lowenthal explains the science behind how it works, describes the launch plans, and discusses an additional indication to be...
Sep 30, 2024
Innovation Day San Diego: Palm Therapeutics is focused on developing palmitoylation targeted therapies
Co-Founder and CEO Andrew Rudd describes how the company is focused on this post translational modification as a drug target. The first...
Sep 27, 2024
Innovation Day San Diego: The founder of San Diego based Resolute Science describes how the company aims to use macrophages to deliver toxic payloads to tumors
A resident company of JLABS @ San Diego, Faith Barnett describes how Resolute is creating "Macrophage Targeted Conjugates" to treat...
Sep 27, 2024
Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates
CEO Marina Udier describes how the company is developing an off the shelf product that includes over 200 neoantigens, a personalized...
Sep 25, 2024
Basel based Anaveon is engineering cytokines to solve the problem of T-cell exhaustion
Co-Founder & CEO Andreas Katopodis describes the company’s three primary programs: a non-specific fusion protein that blocks the alpha...
Sep 25, 2024
Versant Ventures has built a discovery center in Basel called Ridgeline that helps incubate new companies - it has already resulted in successes you will know
Ridgeline president Alex Mayweg and vice president Giorgio Ottaviani describe why the location in Basel and what amenities Ridgeline has...
Sep 24, 2024
Cambridge UK based Constructive Bio announced a $58 million series A today, one of the largest in the UK region
The company is a synthetic bio company that aims to turn living cells into biomanufacturers, for biopharmaceutical purposes and beyond.
Sep 24, 2024
Gameto CEO Dina Radenkovic talks about running a women's health biotech, the development of Fertilo, work on menopause, and more
She describes how Fertilo is being developed to replace hormonal injections and shorten IVF and egg freezing times. Plus, how recent...
Sep 24, 2024
Cambridge UK's PhoreMost, a biotech that specializes in novel ligase discovery for protein degradation and molecular glues, topped up its series B to over $50M this month
CEO Neil Torbett describes the SITESEEKER target ID platform that is the company's foundation. More color on individual programs will be dis
Sep 24, 2024
Zurich based Araris Biotech is developing an ADC conjugation technology that allows for the use of multiple payload classes simultaneously
Acting CEO Dragan Grabulovski describes how they are able to achieve this, the benefits of having multiple payload classes at once, and...
Sep 24, 2024
The CEO of France's Orano Med gives an overview of the radiopharmaceutical approach and why he believes alpha emitters are the way to go
Julien Dodet describes Orano Med's 'lead 212' approach, and discusses pipeline programs, including partnerships with Molecular Partners...
Sep 23, 2024
The Co-Founder & CEO of Zurich based Molecular Partners describes their DARPin technology platform and how it is being put to use
Patrick Amstutz discusses the properties of DARPins that make them ideal building blocks of multispecifics and use cases such as immuno...
Sep 23, 2024
Zurich based CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue
Co-Founder & CEO Christian Leisner describes the M-gager platform and how it allows the company to have high specificity to targets, and...
Sep 23, 2024
Phoenixville, PA based PleoPharma is readying a phase 3 study of its therapy to treat cannabis withdrawal
Co-Founder & CEO Ginger Constantine describes how some people are affected by cannabis withdrawal and discusses the dual action medicine...
Sep 22, 2024
BaseCure Therapeutics is a Delaware area startup that is working on siRNAs for cardiometabolic diseases like hypertension and obesity
Acting CEO Jing Yang says the company's obesity approach will try to avoid the muscle wasting that comes with GLPs by focusing on the fat...
Sep 22, 2024
The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more
Gunilla Osswald talks about the global approvals Leqembi has received, she makes the case for a European approval, and talks about what...
Sep 21, 2024
Stockholm based Guard Therapeutics is trying to harness the natural properties of A1M (alpha-1-microglobulin) to protect the kidney
CEO Tobias Agervald explains how the lead program RMC-035 is being tested in conjunction with open heart surgery while smaller fragments...
Sep 21, 2024
.png){kind=logo}
